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There is a pressing need to develop reliable noninvasive 
approaches for determination of the initial extent of myocar- 
dium at risk during acute myocardial infarction and for early 
assessment of the degree of salvage after reperfusion ther- 
apy. To be clinically useful, the method employed should not 
delay the institution of thrombolytic drug administration, 
should be easy to perform with conventional imaging tech- 
nology available in the community hospital setting and 
should be able to provide information relevant to myocardial 
viability in addition to flow enhancement. 
Thallium-201 imaging to assess coronary reperfusion. 
Myocardial perfusion imaging with thallium-201 has been 
utilized as a method for evaluating the efficacy of coronary 
reperfusion in acute myocardial infarction (1). When thal- 
lium-201 is injected intravenously during the occlusion phase 
(pretreatment), the degree of delayed redistribution after 
thrombolysis is proportional to the degree of flow restoration 
and, presumably, myocardial viability (2,3). Patients dem- 
onstrating successful thrombolysis had more thallium-201 
redistribution and a smaller final thallium defect size in 
relation to prethrombolysis images than were observed in 
patients with a persistently occluded infarct-related vessel, 
who showed little change in defect size (4-6). Reduto et al. 
(4) found that the improvement in thallium-201 uptake on 
redistribution images correlated well with subsequent im- 
provement in left ventricular ejection fraction. 
There are some important limitations to the use of thal- 
lium-201 rest redistribution imaging in evaluating patients 
receiving thrombolytic therapy. First, the time that it takes 
to obtain pretreatment images may delay the institution of 
therapy up to 20 or 30 min. This delay is not feasible because 
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the earlier that reperfusion can be accomplished the greater 
chance there is for benefit in myocardial salvage. Second, if 
thallium-201 is administered for the first time too soon after 
reperfusion, the degree of salvage could be overestimated 
because the tracer is being administered during the phase of 
hyperemia. The result may be “excess” thallium uptake in 
the infarct zone (2,7,8). Third, lack of significant redistribu- 
tion on 3 h to 4 h delayed images does not preclude residual 
myocardial viability. In patients who underwent intravenous 
streptokinase therapy, De Coster et al. (6) reported further 
improvement in thallium-201 uptake in the reperfused zone 
between the 4 h redistribution images and repeat studies 
performed at 4 days and 6 weeks. Furthermore, it has been 
estimated (9) that approximately 30% of persistent thallium 
defects observed on serial exercise scintigrams in patients 
with chronic coronary artery disease will show significantly 
improved early thallium uptake after revascularization. 
Some investigators (10,ll) have advocated repeat imaging at 
24 h to detect presence of “late” redistribution to better 
distinguish scar from ischemia. 
Technetium-99m isonitriles: advantages over thallium. 
The technetium-99m isonitriles have emerged as a new class 
of perfusion agents that, because of superior physical char- 
acteristics, may be more optimal than thallium-201 for myo- 
cardial perfusion imaging. One of these agents, technetium- 
99m methoxy isobutyl isonitrile (MIBI) appears to be an 
appropriate agent to use clinically because of its low level of 
activity in lung and liver tissues (12). 99mTc-MIBI, unlike 
thallium-201, does not redistribute after transient ischemia 
and requires separate injections of the radionuclide to dis- 
tinguish between reversible and irreversible myocardial in- 
jury. Its potential advantages over thallium-201 include 1) its 
140 keV photon energy peak, which is optimal for gamma 
camera imaging and has produced higher quality images than 
those produced by thallium; 2) the shorter half-life and better 
dosimetry make it possible to administer a 10 to 15 times 
higher dose of the radiopharmaceutical than of thallium, 
yielding better images obtained in a shorter time period; 3) 
because of the high 99mTc-MIBI activity, one can combine 
perfusion imaging with assessment of right and left ventric- 
ular ejection fraction by first pass radionuclide angiography; 
4) the high photon flux of 99mTc-MIBI permits electrocardio- 
gram (ECG)-gated image acquisition, thereby allowing wall 
motion analysis from the tine display of the perfusion 
images; 5) because 99mTc-MIBI remains relatively fixed in 
myocardial cells after initial extraction without delayed 
redistribution, it provides information on regional blood flow 
and risk area at the time of its administration. 
Thus, the radionuclide has potential to be superior to 
thallium-201 for assessment of hypoperfusion and viability in 
the setting of thrombolytic therapy. One can administer the 
01989 by the American College of Cardiology 0735-1097/89/$3.50 
JACC Vol. 14. No. 4 BELLER 875 
October 1989:874-6 EDITORIAL COMMENT 
first dose of 99mTc-MIBI just before thrombolytic therapy. 
but can postpone imaging several hours after drug adminis- 
tration to obtain the pretreatment assessment of risk area, so 
as not to delay institution of thrombolysis. A second injec- 
tion can then be performed after thrombolytic therapy to 
delineate the degree of improvement in flow and extent of 
myocardial salvage. Several experimental studies have been 
undertaken to validate this assumption (13,14). 
The present study. In this issue of the Journal, Wackers 
and his colleagues (15) from several collaborating institu- 
tions have successfully applied serial 99mTc-MIBI imaging in 
patients with acute myocardial infarction undergoing throm- 
bolytic therapy. Area at risk was determined from initial 
images delineating the perfusion pattern before initiation of 
thrombolytic therapy. There was no delay in instituting 
prompt therapy because these pretreatment images were 
processed several hours after administration of recombinant 
tissue-type plasminogen activator (rt-PA). Because of the 
lack of redistribution of 99mTc-MIBI, these images should 
accurately reflect the area at risk. Patients with a patent 
infarct artery had a significantly greater decrease in defect 
size on repeat images performed 18 to 48 h after throm- 
bolytic therapy than did patients with persistently occluded 
vessels. 
Some ndditional interesting observations Msere made in 
this study. First. the size of the area at risk varied markedly 
among the patients in this study, and there was no obvious 
relation between extent of underlying coronary artery dis- 
ease or presence of coronary collateral flow and the area at 
risk, Second, 7 of the 23 patients receiving rt-PA had no 
change in defect size from the immediate to the follow-up 
study, a finding that should not necessarily imply failure to 
achieve reflow. If a high grade residual stenosis was present 
after clot lysis, causing a persistent diminution in resting 
flow, this might contribute to the residual defect size. When 
99mTc-MIBI is administered in this setting, uptake will be 
reduced in the irreversibly injured region as well as in the 
hypoperfused peri-infarction zone. This reduction would 
yield a defect after reperfusion that was larger than the 
extent of necrotic myocardium. Thus, the presence of a 
severe residual stenosis would contribute to underestimation 
with 99mTc-MIBI of degree of viability. If thallium-201 is 
administered under such circumstances after reperfusion. 
there would be an initial defect encompassing both the 
necrotic and ischemic zones. Delayed imaging 2 to 4 h later 
would show rest thallium redistribution in the myocardial 
region that remained underperfused because of the residual 
stenosis but was, in fact, salvaged by reflow through the 
previously occluded vessel. 
Third, there M’as only an average 36% reduction in 
relative dqfect size after thromholytic therapy in this group 
of patients treated within 4 h of onset of chest pain. This 
does not seem like a great change, but it must be enough to 
correlate with improved survival and enhanced left ventric- 
ular function, as reported in multiple series of patients 
receiving thrombolytic therapy in this time frame. However, 
as previously observed with thallium-201 studies (6), certain 
patients in this study showed further reduction in 99mT~- 
MIBI defect size at days 6 to 14. Hence, ultimate degree of 
salvage may be underestimated on early post-thrombolytic 
images. Could this continuing improvement in MIBI uptake 
be attributed to further increase in nutrient coronary blood 
flow. reversal of ischemic alterations in MIBI intracellular 
extraction, or both? Further investigation is warranted in 
this regard. Sinusas et al. (16) showed that ischemia alone, or 
postischemic dysfunction (“stunning”), did not affect myo- 
cardial uptake of 99mTc-MIBI. 
Clinical implications. Wackers and co-workers (15) found 
that a relative decrease by >30% in the size of the 99mTc- 
MIBI perfusion defect predicted patency of the infarct- 
related artery providing evidence obtained noninvasively of 
the efficacy of treatment. This is an important observation 
because we have few reliable non-angiographic methods to 
predict successful reperfusion. 99mTc-MIBI imaging could 
become a useful technique to incorporate in future clinical 
research trials assessing efficacy of pharmacologic ap- 
proaches for reperfusion. 
Finally. hoM> might serial myocardial perfusion imaging 
with 99’nTc-MIBI he incorporated in the acute management 
of myocardial infarction to better select patients receiving 
thromholytic therapy for early coronary angiography? First, 
a “split dose” technique for serial 99mTc-MIBI imaging 2 h 
apart will have to be developed. This might involve com- 
puter subtraction of the pretreatment 99mTc-MIBI activity 
(because it will not have decayed) from the posttreatment 
images obtained only several hours instead of 18 to 48 h 
later, as performed in the study by Wackers et al. (15). If the 
area at risk is small on the pretreatment images, then it 
wouldn’t matter what the posttreatment images demon- 
strated because the patient would be in a low risk category. 
This pattern might be observed in a significant number of 
patients with inferior infarction. If the area at risk on the 
prethrombolytic images was large and a significant reduction 
in defect size was seen on repeat posttreatment images, then 
adequate reperfusion had probably occurred and early angi- 
ography would not be required. In contrast, if the area at risk 
was large initially and remained unchanged on repeat imag- 
ing after completion of the thrombolytic protocol, it could be 
inferred that infarct vessel patency had not been restored. 
Wackers et al. (1.5) found an inverse relation between left 
ventricular ejection fraction at hospital discharge and the 
size of the 99mTc-MIBI myocardial perfusion defect prior to 
treatment. Thus, early angiography with a view toward 
angioplasty to establish reflow and enhance myocardial 
salvage could benefit patients who fail to show a reduction of 
a large perfusion defect with thrombolytic therapy alone. 
This might truly be considered a “rescue angioplasty.” 
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Conclusions. From both experimental data and the early 
clinical experience reported by Wackers and colleagues (151, 
it appears that serial 99mTc-MIBI imaging may accurately 
reflect the risk area at the time of coronary occlusion and 
noninvasively determine degree of reflow and extent of 
myocardial salvage after thrombolytic therapy. Although the 
value and limitations of this new perfusion imaging approach 
need to be more precisely delineated in further prospective 
studies with larger numbers of patients, this initial experi- 
ence is certainly encouraging. 
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